Bank Of New York Mellon Corp Cellectar Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.5 - $6.9 $2,208 - $4,353	-631 Reduced 0.52%	121,107 $49,000
Q3 2021 Nov 12, 2021	BUY	$8.2 - $12.4 $763,657 - $1.15 Million	93,129 Added 325.52%	121,738 $113,000
Q1 2021 May 13, 2021	SELL	$15.2 - $25.0 $47,120 - $77,500	-3,100 Reduced 9.78%	28,609 $460,000
Q4 2020 Feb 09, 2021	BUY	$11.2 - $27.7 $355,140 - $878,339	31,709 New	31,709 $659,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.